Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metagenics gets Amway parent's support

This article was originally published in The Tan Sheet

Executive Summary

Metagenics, a manufacturer of medical foods and nutraceuticals marketed to health care professionals, attracts financial support from Amway parent Alticor. The firms did not disclose details of the deal in their Aug. 11 release, but said Metagenics, which had sales of more than $200 million in 2008, will continue to operate as a stand-alone company. Metagenics gains "access to financial resources to support our internal growth and our acquisition strategy," CEO Jeffrey J. Katke said in an Aug. 13 e-mail. The San Clemente, Calif.-based firm owns proprietary formulas for use in nutraceuticals, medical foods and drugs. Amway's Nutrilite supplement and food line accounted for $3 billion of Ada, Mich.-based Alticor's worldwide sales of more than $8.2 billion in its fiscal year 2008

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel